Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Clinical trial NCT07120451 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07120451
- Sponsor
- Fudan University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-10
- Primary completion
- 2026-10-31
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.